[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.89.187. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
June 19, 2013

Real-world Experience in the Midst of an Exserohilum Meningitis Outbreak

Author Affiliations

Author Affiliations: Departments of Medical Microbiology and Immunology and Internal Medicine, Division of Infectious Diseases, University of California, Davis (Dr Thompson); Departments of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston (Dr Kontoyiannis); Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center, San Antonio (Dr Patterson); and South Texas Veterans Health Care System, San Antonio (Dr Patterson).

JAMA. 2013;309(23):2493-2495. doi:10.1001/jama.2013.6294

The outbreak of invasive fungal infections among patients who received injections of contaminated methylprednisolone acetate from the New England Compounding Center continues.

New cases have been reported to the Centers for Disease Control and Prevention weekly and more than 740 patients in 20 states have been diagnosed with meningitis, spinal or paraspinal infections, or joint infections (ie, epidural abscess, phlegmon, diskitis, vertebral osteomyelitis, arachnoiditis, or other complications at or near the injection site).1

First Page Preview View Large
First page PDF preview
First page PDF preview
×